BioCentury | Jan 26, 2021
Product Development

Trials of colchicine for COVID-19: Data Byte

Phase III data from the Montreal Heart Institute suggests colchicine could serve as an oral alternative to IV-infused mAbs for COVID-19 in the outpatient setting, but more data are needed. The COLCORONA trial did not...
BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

As emerging therapeutic modalities move toward mainstream, a flood of new companies has arisen to break through the limitations of first-generation technologies and expand the reach of gene and cell therapies,...
BioCentury | Jan 22, 2021
Product Development

Slaoui on Warp Speed’s successes, limitations and lessons

Having helped create the fastest vaccine development programs in history, Moncef Slaoui has stepped down as scientific adviser and co-leader of Operation Warp Speed, the U.S. government’s initiative to develop, manufacture and distribute countermeasures to COVID-19. Slaoui and...
BioCentury | Jan 22, 2021
Emerging Company Profile

SciNeuro reunites GSK R&D vets to bring CNS therapies to China

Led by GSK neuro R&D alumni and fueled by $100 million in series A funds, SciNeuro aims to develop  neurodegeneration and neuropsychiatric therapies for the Greater China market through a mix of partnering and in-house R&D....
BioCentury | Jan 20, 2021
Finance

IPO queue bulges further as Adagene, NexImmune are among latest to file

After a record year for NASDAQ listings, a burgeoning queue of biopharmas seeking IPOs in 2021 swelled further late Tuesday as immuno-oncology companies Adagene and NexImmune filed for offerings. The pair joined seven therapeutics developers...
BioCentury | Jan 20, 2021
Product Development

RA readout drives Aclaris’ first big gain since shifting focus to innovative immunology pipeline

An efficacy readout in a small Phase IIa trial of Aclaris’ oral therapy for rheumatoid arthritis has more than tripled the company’s market cap, representing its first major value-creating event since it restructured in 2H19...
BioCentury | Jan 12, 2021
Product Development

Lilly’s amyloid therapy not a big step forward from Biogen’s

With a more sophisticated protocol for selecting patients and positive Phase II data in hand, Eli Lilly is heading into a confirmatory trial of its Alzheimer’s therapy donanemab in an arguably stronger...
BioCentury | Jan 12, 2021
Emerging Company Profile

Atalanta’s next-gen RNAi branches deeper into brain, hooks Biogen and Genentech

A rush of interest following the publication of Atalanta’s brain-optimized siRNA tech enabled the UMass Medical School spinout to launch with two high-profile partners in hand. Atalanta Therapeutics Inc....
BioCentury | Jan 11, 2021
Politics, Policy & Law

Trump administration drops defense of ‘most favored nation’ price controls, leaves issue in Biden’s hands

In the face of defeats in three federal courts, the Trump administration has abandoned its attempt to use an administrative shortcut to impose a “most favored nation” international reference pricing scheme on Medicare Part B...
BioCentury | Jan 9, 2021
Tools & Techniques

What DeepMind’s leap means for structure-based drug developers

The step change in protein folding prediction pioneered by Alphabet’s DeepMind stands to widen the funnel of targets tackled with structure-based platforms, including newly discovered proteins from...
Items per page:
1 - 10 of 3299